Stereotaxis, Inc. (STXS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Stereotaxis, Inc. (STXS) Healthcare & Pipeline Overview

Stereotaxis, Inc. pioneers robotic magnetic navigation (RMN) systems for minimally invasive cardiac procedures, offering precision and control in catheter placement. With its Genesis RMN system and related technologies, the company aims to enhance treatment efficacy and safety in electrophysiology, operating within the growing market for advanced medical robotics.

What Is the Investment Thesis for STXS?

Stereotaxis, Inc. presents a compelling, albeit high-risk, investment thesis centered on its innovative robotic magnetic navigation (RMN) technology for cardiac procedures. The company's Genesis RMN system offers the potential to improve precision and outcomes in electrophysiology, addressing a significant market need. Key value drivers include increased adoption of robotic technology in cardiac ablation, driven by clinical data supporting improved efficacy and safety. The collaboration with Osypka AG to develop a magnetic ablation catheter represents a potential growth catalyst. However, the company's negative profit margin of -66.8% and a relatively small market capitalization of $127M highlight the risks associated with investing in a growth-stage medical device company. Successful commercialization of new products and expansion of the installed base are critical for achieving profitability and long-term value creation.

Based on FMP financials and quantitative analysis

STXS Key Highlights

Market capitalization of $127M reflects the company's size and growth potential in the medical robotics market.

• Gross margin of 52.7% indicates a strong pricing power and efficient cost management in its core product offerings.
• Profit margin of -66.8% highlights the company's current challenges in achieving profitability, requiring focus on revenue growth and cost optimization.
• Beta of 1.42 suggests higher volatility compared to the overall market, reflecting the speculative nature of the stock.
• No dividend is currently offered, indicating that the company is reinvesting its earnings to fuel growth initiatives.

Who Are STXS's Competitors?

STXS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STXS's Key Strengths?

Proprietary robotic magnetic navigation (RMN) technology.

• Potential for improved precision and safety in cardiac procedures.
• Established relationships with leading medical centers.
• Strategic collaboration with Osypka AG.

What Are STXS's Weaknesses?

Negative profit margin and limited financial resources.

• Small installed base of RMN systems.
• Dependence on a limited number of key products.
• High capital expenditure requirements for RMN system installations.

What Could Drive STXS Stock Higher?

Potential regulatory approvals for new robotic ablation catheters developed in collaboration with Osypka AG.

• Increasing adoption of robotic technology in cardiac ablation procedures.
• Publication of clinical data demonstrating the benefits of RMN technology.
• Expansion of the installed base of Genesis RMN systems.

What Are the Key Risks for STXS?

Financial-distress signal — its Altman Z-Score of -13.53 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established players in the electrophysiology market.
• Technological advancements that could render RMN technology obsolete.
• Regulatory hurdles and reimbursement challenges.
• Product liability risks associated with medical devices.
• Dependence on a limited number of key products.

What Are the Growth Opportunities for STXS?

• Growth opportunity 1: Expanding the installed base of Genesis RMN systems represents a significant growth opportunity. The market for robotic cardiac ablation is projected to grow as hospitals and physicians recognize the benefits of increased precision and reduced radiation exposure. Stereotaxis can capitalize on this trend by demonstrating the clinical and economic value of its technology through clinical studies and partnerships with leading medical centers. The timeline for this growth is ongoing, with potential for accelerated adoption over the next 3-5 years.
• Growth opportunity 2: Developing and commercializing new robotic ablation catheters in collaboration with Osypka AG offers a pathway to expand the company's product portfolio and address a broader range of cardiac arrhythmias. The magnetic ablation catheter is expected to provide enhanced control and efficacy in ablating complex arrhythmias. The timeline for this growth is dependent on regulatory approvals and successful product launch, with potential for market entry within the next 2-3 years.
• Growth opportunity 3: Increasing utilization of existing RMN systems by expanding the range of procedures performed robotically can drive revenue growth. Stereotaxis can work with hospitals and physicians to develop new protocols and techniques for using its technology in various cardiac interventions. This growth opportunity is ongoing, with potential for incremental revenue gains as physicians become more comfortable and proficient with robotic navigation.
• Growth opportunity 4: Expanding into new geographic markets, particularly in Asia and Europe, offers a significant growth opportunity. The demand for advanced medical technologies is increasing in these regions, driven by rising healthcare expenditures and a growing aging population. Stereotaxis can leverage its existing distribution network and establish new partnerships to penetrate these markets. The timeline for this expansion is dependent on regulatory approvals and market entry strategies, with potential for significant growth over the next 5-7 years.
• Growth opportunity 5: Leveraging the Odyssey information management system to provide data-driven insights and improve workflow efficiency can drive adoption and customer loyalty. The Odyssey system enables hospitals to manage, control, record, and share procedural data, providing valuable information for optimizing clinical outcomes and operational performance. Stereotaxis can enhance the value proposition of its RMN systems by integrating Odyssey with other hospital information systems and offering data analytics services. The timeline for this growth is ongoing, with potential for continuous improvement and innovation in data management and analytics.

What Are STXS's Competitive Advantages?

• Proprietary robotic magnetic navigation (RMN) technology protected by patents.
• High switching costs for hospitals and physicians due to training and infrastructure investments.
• Established relationships with leading medical centers and key opinion leaders.
• Strategic collaboration with Osypka AG to develop innovative ablation catheters.

What Does STXS Do?

Stereotaxis, Inc., founded in 1990 and headquartered in St. Louis, Missouri, is a healthcare technology company focused on designing, manufacturing, and marketing robotic systems and instruments for interventional procedures. The company's core technology revolves around robotic magnetic navigation (RMN) systems, including the Genesis RMN and Niobe systems. These systems enable physicians to navigate catheters and guidewires through blood vessels and heart chambers with enhanced precision and stability, guided by real-time imaging. Stereotaxis's product portfolio includes the Odyssey information management system, which facilitates procedure recording and sharing, and the Stereotaxis Imaging Model S X-ray system, designed for robotic interventional operating rooms. The company also offers a range of disposable products, such as the QuikCAS automated catheter advancement system, and markets various diagnostic and ablation catheters. Stereotaxis distributes its products through a direct sales force, distributors, and sales agents, serving hospitals and medical centers globally. A strategic collaboration with Osypka AG aims to develop a magnetic ablation catheter, integrating Stereotaxis's robotic technology to further advance cardiac ablation procedures.

What Products and Services Does STXS Offer?

• Design, manufacture, and market robotic systems for interventional cardiology.
• Provide robotic magnetic navigation (RMN) systems for precise catheter navigation.
• Offer the Genesis RMN and Niobe systems for image-guided delivery of catheters.
• Develop the Odyssey information solution for managing and sharing procedural data.
• Market the Stereotaxis Imaging Model S X-ray system for robotic operating rooms.
• Provide disposable products like QuikCAS for automated catheter advancement.
• Collaborate with Osypka AG to develop magnetic ablation catheters.

How Does STXS Make Money?

• Sales of robotic magnetic navigation (RMN) systems to hospitals and medical centers.
• Recurring revenue from sales of disposable products used with the RMN systems.
• Service and maintenance contracts for installed RMN systems.
• Sales of the Odyssey information management system and related services.

What Industry Does STXS Operate In?

Stereotaxis operates within the medical instruments and supplies industry, a segment experiencing growth driven by technological advancements and increasing demand for minimally invasive procedures. The electrophysiology market, where Stereotaxis's RMN systems are primarily used, is expected to grow as the prevalence of atrial fibrillation and other cardiac arrhythmias rises. Competition includes established players in the electrophysiology space, such as Johnson & Johnson (Biosense Webster), Abbott, and Boston Scientific, as well as emerging companies focused on robotic surgery and navigation. Stereotaxis differentiates itself through its unique magnetic navigation technology, offering potential advantages in precision and safety compared to traditional manual techniques.

Who Are STXS's Key Customers?

• Hospitals and medical centers performing interventional cardiology procedures.
• Electrophysiologists specializing in the treatment of cardiac arrhythmias.
• Interventional cardiologists performing catheter-based procedures.
• Research institutions conducting clinical studies on robotic cardiac interventions.

Company Profile

Stereotaxis, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in St. Louis, US. The company is led by CEO David L. Fischel. STXS has traded publicly since 2004.

Key Financial Metrics

Return on assets is -40.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.9%, the inverse of the P/E and a quick read on earnings relative to price.

STXS Valuation & Market Position

With a $127M market cap, Stereotaxis, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $3.50 to $3.50, with a consensus of $3.50. At the current price of $1.30, that implies approximately 169% upside potential. Relative to its peer group, STXS's quantitative score of 18/100 is below the peer average of 68/100.

Quarterly Financial Performance: Stereotaxis, Inc.

Revenue for Stereotaxis, Inc. came in at $7.7M during Q2 FY2026, a 21.9% improvement versus the preceding quarter. The company recorded a net loss of $4.5M, with diluted EPS of $-0.04. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, STXS averaged $-0.06 in diluted EPS.

Stereotaxis, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.53 places it in the distress zone, a signal of elevated financial risk.

Stereotaxis, Inc. has missed Wall Street's EPS estimate in 2 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 0.8% below estimates on average.

Over the past six months, Stereotaxis, Inc. insiders filed 7 SEC Form 4 transactions — 0 sales and 7 purchases. On net that is roughly 299K shares acquired (about $75K) — insiders putting money in tends to read as conviction.

STXS Financials

STXS Latest News

STXS Analyst Consensus

STXS MoonshotScore

STXS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources